Compare Stocks: VANI, COCH, RLMD, and AVIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.64 -3.3%	$5.06	$2.78 ▼ $6.45	$453.59M	0.28	402,037 shs	95,420 shs
COCH Envoy Medical	$0.71 +0.6%	$0.72	$0.36 ▼ $1.89	$55.11M	1.91	449,725 shs	44,534 shs
RLMD Relmada Therapeutics	$4.27 -3.7%	$5.24	$1.44 ▼ $8.00	$455.69M	0.45	1.49 million shs	1.01 million shs
VANI Vivani Medical	$1.38 -7.7%	$1.37	$0.92 ▼ $1.92	$124.03M	2.36	352,063 shs	418,799 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	+8.97%	+11.05%	+33.72%	+73.00%
COCH Envoy Medical	0.00%	-2.61%	+5.78%	+14.52%	-46.21%
RLMD Relmada Therapeutics	0.00%	+1.61%	-10.32%	-29.35%	+168.48%
VANI Vivani Medical	0.00%	+7.19%	+5.67%	+30.70%	+15.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.64 -3.3%	$5.06	$2.78 ▼ $6.45	$453.59M	0.28	402,037 shs	95,420 shs
COCH Envoy Medical	$0.71 +0.6%	$0.72	$0.36 ▼ $1.89	$55.11M	1.91	449,725 shs	44,534 shs
RLMD Relmada Therapeutics	$4.27 -3.7%	$5.24	$1.44 ▼ $8.00	$455.69M	0.45	1.49 million shs	1.01 million shs
VANI Vivani Medical	$1.38 -7.7%	$1.37	$0.92 ▼ $1.92	$124.03M	2.36	352,063 shs	418,799 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	+8.97%	+11.05%	+33.72%	+73.00%
COCH Envoy Medical	0.00%	-2.61%	+5.78%	+14.52%	-46.21%
RLMD Relmada Therapeutics	0.00%	+1.61%	-10.32%	-29.35%	+168.48%
VANI Vivani Medical	0.00%	+7.19%	+5.67%	+30.70%	+15.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	21.36% Upside
COCH Envoy Medical	2.00	Hold	$2.00	179.72% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	178.75% Upside
VANI Vivani Medical	2.25	Hold	$3.75	174.73% Upside

Current Analyst Ratings Breakdown

Latest VANI, COCH, RLMD, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	COCH Envoy Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.50 ➝ $2.00
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
7/27/2026	COCH Envoy Medical	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
7/21/2026	COCH Envoy Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	COCH Envoy Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/23/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/18/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
COCH Envoy Medical	$240K	229.96	N/A	N/A	($0.42) per share	-1.70
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
COCH Envoy Medical	-$23.76M	-$0.76	N/A	N/A	N/A	-11,304.83%	N/A	-144.13%	11/9/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)

Latest VANI, COCH, RLMD, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/10/2026	Q2 2026	COCH Envoy Medical	-$0.08	-$0.07	+$0.01	-$0.07	$0.05 million	$0.05 million
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COCH Envoy Medical	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
COCH Envoy Medical	N/A	1.73	1.61
RLMD Relmada Therapeutics	N/A	29.52	29.52
VANI Vivani Medical	N/A	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
COCH Envoy Medical	8.59%
RLMD Relmada Therapeutics	45.24%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
COCH Envoy Medical	7.20%
RLMD Relmada Therapeutics	14.50%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	80.21 million	62.88 million	Optionable
COCH Envoy Medical	34	77.19 million	71.64 million	Not Optionable
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable
VANI Vivani Medical	20	90.20 million	42.13 million	Optionable

VANI, COCH, RLMD, and AVIR Headlines

Recent News About These Companies

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences

September 3, 2026 | quiverquant.comQ

Vivani Medical Announces Participation in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)

August 20, 2026 | theglobeandmail.com

Vivani Medical Inc U5P

August 19, 2026 | morningstar.comM

Vivani Medical Updates Investors with Regulation FD Presentation

August 17, 2026 | tipranks.com

Wall Street Zen Upgrades Vivani Medical (NASDAQ:VANI) to "Hold"

August 15, 2026 | marketbeat.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | finance.yahoo.com

Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 13, 2026 | marketbeat.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6, 2026 | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6, 2026 | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6, 2026 | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6, 2026 | tipranks.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

Vivani Medical signs agreement with Novo Nordisk to evaluate NPM-139

July 9, 2026 | pharmabiz.comP

Ozempic & Wegovy maker to evaluate long-acting GLP-1 implant that could last up to a year

July 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, RLMD, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$5.64 -0.19 (-3.26%)

As of 03:36 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Envoy Medical NASDAQ:COCH

$0.71 +0.00 (+0.56%)

As of 03:35 PM Eastern

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Relmada Therapeutics NASDAQ:RLMD

$4.26 -0.17 (-3.72%)

As of 03:35 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Vivani Medical NASDAQ:VANI

$1.38 -0.12 (-7.72%)

As of 03:35 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VANI, COCH, RLMD, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VANI, COCH, RLMD, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VANI, COCH, RLMD, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, RLMD, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Envoy Medical NASDAQ:COCH

Relmada Therapeutics NASDAQ:RLMD

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VANI, COCH, RLMD, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VANI, COCH, RLMD, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VANI, COCH, RLMD, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, RLMD, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Envoy Medical NASDAQ:COCH

Relmada Therapeutics NASDAQ:RLMD

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools